Newsquawk Logo

Merck (MRK) announces late-breaking data from Phase 3 trials, evaluating oravirine/islatravir (DOR/ISL), an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1

Merck's announcement on late-breaking data from Phase 3 trials for its investigational HIV treatment could impact both its stock and broader market sentiment around pharmaceutical innovations.

Newsquawk StaffPublished On the live feed at — 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Google (GOOGL) will reportedly test changes to its search engine results following EU antitrust charges, will apply initially to searches for lodgings, according to reports

White House Official says Amazon (AMZN), Google (GOOGL), and Oracle (ORCL) are to sign data centre agreements, Fox News reports

Merck (MRK) announces late-breaking data from Phase 3 trials, evaluating oravirine/islatravir (DOR/ISL), an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1

Elliott assures UK over future of the London Stock Exchange, the activist has privately assured the government that it is not pushing for a spin-off of the exchange, via FT

Anthropic acquires Vercept to advance Claude's computer use capabilities; Vercept will wind down its external product in coming weeks & join Anthropic in pushing frontiers of computer use

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

Given the significance of effective HIV therapies, a positive outcome could not only support Merck’s future revenue streams but also enhance investor confidence in the biotech sector as a whole.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.